AIMS/HYPOTHESIS: We sought to determine the impact of long-standing type 1 diabetes on haematopoietic stem/progenitor cell (HSC) number and function and to examine the impact of modulating glycoprotein (GP)130 receptor in these cells. METHODS: Wild-type, gp130(-/-) and GFP chimeric mice were treated with streptozotocin to induce type 1 diabetes. Bone marrow (BM)-derived cells were used for colony-formation assay, quantification of side population (SP) cells, examination of gene expression, nitric oxide measurement and migration studies. Endothelial progenitor cells (EPCs), a population of vascular precursors derived from HSCs, were compared in diabetic and control mice. Cytokines were measured in BM supernatant fractions by ELISA and protein array. Flow cytometry was performed on enzymatically dissociated retina from gfp(+) chimeric mice and used to assess BM cell recruitment to the retina, kidney and blood. RESULTS: BM cells from the 12-month-diabetic mice showed reduced colony-forming ability, depletion of SP-HSCs with a proportional increase in SP-HSCs residing in hypoxic regions of BM, decreased EPC numbers, and reduced eNos (also known as Nos3) but increased iNos (also known as Nos2) and oxidative stress-related genes. BM supernatant fraction showed increased cytokines, GP130 ligands and monocyte/macrophage stimulating factor. Retina, kidney and peripheral blood showed increased numbers of CD11b(+)/CD45(hi)/ CCR2(+)/Ly6C(hi) inflammatory monocytes. Diabetic gp130(-/-) mice were protected from development of diabetes-induced changes in their HSCs. CONCLUSIONS/ INTERPRETATION: The BM microenvironment of type 1 diabetic mice can lead to changes in haematopoiesis, with generation of more monocytes and fewer EPCs contributing to development of microvascular complications. Inhibition of GP130 activation may serve as a therapeutic strategy to improve the key aspects of this dysfunction.
AIMS/HYPOTHESIS: We sought to determine the impact of long-standing type 1 diabetes on haematopoietic stem/progenitor cell (HSC) number and function and to examine the impact of modulating glycoprotein (GP)130 receptor in these cells. METHODS: Wild-type, gp130(-/-) and GFP chimeric mice were treated with streptozotocin to induce type 1 diabetes. Bone marrow (BM)-derived cells were used for colony-formation assay, quantification of side population (SP) cells, examination of gene expression, nitric oxide measurement and migration studies. Endothelial progenitor cells (EPCs), a population of vascular precursors derived from HSCs, were compared in diabetic and control mice. Cytokines were measured in BM supernatant fractions by ELISA and protein array. Flow cytometry was performed on enzymatically dissociated retina from gfp(+) chimeric mice and used to assess BM cell recruitment to the retina, kidney and blood. RESULTS: BM cells from the 12-month-diabeticmice showed reduced colony-forming ability, depletion of SP-HSCs with a proportional increase in SP-HSCs residing in hypoxic regions of BM, decreased EPC numbers, and reduced eNos (also known as Nos3) but increased iNos (also known as Nos2) and oxidative stress-related genes. BM supernatant fraction showed increased cytokines, GP130 ligands and monocyte/macrophage stimulating factor. Retina, kidney and peripheral blood showed increased numbers of CD11b(+)/CD45(hi)/ CCR2(+)/Ly6C(hi) inflammatory monocytes. Diabeticgp130(-/-) mice were protected from development of diabetes-induced changes in their HSCs. CONCLUSIONS/ INTERPRETATION: The BM microenvironment of type 1 diabeticmice can lead to changes in haematopoiesis, with generation of more monocytes and fewer EPCs contributing to development of microvascular complications. Inhibition of GP130 activation may serve as a therapeutic strategy to improve the key aspects of this dysfunction.
Authors: Cindy Jm Loomans; Rien van Haperen; Jacques M Duijs; Caroline Verseyden; Rini de Crom; Pieter Jm Leenen; Hemmo A Drexhage; Hetty C de Boer; Eelco Jp de Koning; Ton J Rabelink; Frank Jt Staal; Anton Jan van Zonneveld Journal: Mol Med Date: 2009-03-11 Impact factor: 6.354
Authors: Yagna P R Jarajapu; Sergio Caballero; Amrisha Verma; Takahiko Nakagawa; Margaret C Lo; Qiuhong Li; Maria B Grant Journal: Invest Ophthalmol Vis Sci Date: 2011-07-07 Impact factor: 4.799
Authors: Francesca Ferraro; Stefania Lymperi; Simón Méndez-Ferrer; Borja Saez; Joel A Spencer; Beow Y Yeap; Elena Masselli; Gallia Graiani; Lucia Prezioso; Elisa Lodi Rizzini; Marcellina Mangoni; Vittorio Rizzoli; Stephen M Sykes; Charles P Lin; Paul S Frenette; Federico Quaini; David T Scadden Journal: Sci Transl Med Date: 2011-10-12 Impact factor: 17.956
Authors: Katherine A Gallagher; Zhao-Jun Liu; Min Xiao; Haiying Chen; Lee J Goldstein; Donald G Buerk; April Nedeau; Stephen R Thom; Omaida C Velazquez Journal: J Clin Invest Date: 2007-05 Impact factor: 14.808
Authors: Katrin Schröder; Andreas Kohnen; Alexandra Aicher; Elisa A Liehn; Tom Büchse; Stefan Stein; Christian Weber; Stefanie Dimmeler; Ralf P Brandes Journal: Circ Res Date: 2009-08-13 Impact factor: 17.367
Authors: Cristiano P Vieira; Seth D Fortmann; Masroor Hossain; Ana Leda Longhini; Sandra S Hammer; Bright Asare-Bediako; David K Crossman; Micheli S Sielski; Yvonne Adu-Agyeiwaah; Mariana Dupont; Jason L Floyd; Sergio Li Calzi; Todd Lydic; Robert S Welner; Gary J Blanchard; Julia V Busik; Maria B Grant Journal: JCI Insight Date: 2020-07-09
Authors: James M Dominguez; Ping Hu; Sergio Caballero; Leni Moldovan; Amrisha Verma; Gavin Y Oudit; Qiuhong Li; Maria B Grant Journal: Am J Pathol Date: 2016-05-10 Impact factor: 4.307
Authors: Eleni Beli; James M Dominguez; Ping Hu; Jeffrey S Thinschmidt; Sergio Caballero; Sergio Li Calzi; Defang Luo; Sumathi Shanmugam; Tatiana E Salazar; Yaqian Duan; Michael E Boulton; Susanna Mohr; Steven F Abcouwer; Daniel R Saban; Jeffrey K Harrison; Maria B Grant Journal: J Mol Med (Berl) Date: 2016-06-25 Impact factor: 4.599